Ligand Pharmaceuticals, Inc. (NASDAQ: LGND) Starts Presentation at 30th Annual ROTH Conference
Ligand Pharmaceuticals (NASDAQ: LGND) is focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. The company’s Captisol® platform technology is a patent-protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. OmniAb® is a patent-protected transgenic animal platform used in the discovery of fully human mono- and bispecific therapeutic antibodies. The company partners with other pharmaceutical companies to ultimately generate further revenue. Such alliances, licenses and other business relationships include Novartis, Amgen, Merck, Pfizer, Celgene, Gilead, Janssen, Baxter International and Eli Lilly. For more information, visit the company’s website…







